Close Window Close Window
SMis 5th Annual Biosimilars USA Conference
Renaissance Woodbridge Hotel, New Jersey
14/11/2018 - 15/11/2018
URL:   Click here for the event website.
Building on the success of previous events, SMi proudly announces the return of its 5th Annual Biosimilars USA Conference, taking place in New Jersey on the 14th and 15th November 2018.

This fifth annual event will gather a global audience of biosimilar experts and industry-thought leaders to discuss biosimilar manufacturing and commercialization considerations specific to the U.S.

Fresh from the press: On March 7th, 2018, the U.S.-FDAs Commissioner, Scott Gottlieb, MD, announced that Biosimilar medicines are now a top priority for the FDA. Join us this November to learn how to take advantage of the FDAs focus on biosimilars, accelerate your biosimilar pipeline and achieve FDA approval.

Hear from a selection of carefully handpicked keynote addresses and case studies presented to you by top manufacturing and leading distributors of market approved biosimilars, as they offer a unique insight into the areas of manufacturing, commercialization, device design, uptake, switching, interchangeability, and regulations.

This event is CPD accredited.


Tuesday 25th September 2018, Copthorne Tara Hotel, Central London, UK

08.30 - 12.30
Workshop A: Decoding how Stakeholders may Drive Biosimilar Adoption
Workshop Leaders: Tucker Herbert, Manager, ZS Associates
Christina Corridon, Associate Principal, ZS Associates

13.30 - 17.00
Workshop B: Dealing with Life Sciences Patents at the PTAB
Workshop Leaders: Ha Kung Wong, Partner, New York, Fitzpatrick, Cella, Harpper & Scinto
John Kirkland, Director, Intellectual Property, Alkermes, Inc.
Close Window